Abstract
A very brief approach to the whole problem of the limited choice of activating drugs for the family of natural receptors, linked to G-protein (G-Protein-Coupled Receptors or G.P.C.Rs) is to modify them, with appropriate chemogenetical methods, so that they can be recognized by binders and then can be activated by them. After targeted molecular mutation of G.P.C.Rs, artificial receptors are obtained, which are activated exclusively by artificial drugs (Designer Receptors Exclusively Activated by Designer Drugs or D.R.E.A.D.Ds), which are now activated by various C.N.O substances, mainly specific substances. Cells of interest, usually neurons, have either an inhibitory or a sedative or a coordinating effect on the signaling pathways of nerve cells. The result is usually a change in the behavior of mammals, in the field of memory, learning, emotions, etc., so they are a promising process for the treatment of neurodegenerative diseases, in the first phase.
This is a preview of subscription content, log in via an institution to check access.
References
Albert PR, Robillard L 2002 G protein specificity: traffic direction required. Cell Signal 14(5):407–418. https://doi.org/10.1016/s0898-6568(01)00259-5. https://sciencedirect.com/science/article/abs/pii/S0898656801002595?via%3Dihub
Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA, Nonneman RJ, Hartmann J, Moy SS, Nicolelis MA, McNamara JO, Roth BL (2009) Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63:27–39. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751885/pdf/nihms-131523.pdf
Armbruster BN, Xiang L, Pausch MH, Herlitze S, Roth BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A 104:5163–5168. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1829280/pdf/zpq5163.pdf
Campbell EJ, Marchant NJ (2018) The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats. Br J Pharmacol 175(7):994–1003. https://doi.org/10.1111/bph.14146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843707/pdf/BPH-175-994.pdf
Chang WH, Lin SK, Lane HY, Wei FC, Hu WH, Lam YW, Jann MW (1998) Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 22:723–739. https://www.pubmed.ncbi.nlm.nih.gov/9723115/
Chun L, Zhang WH, Liu JF (2012) Structure and ligand recognition of class C GPCRs. Acta Pharmacol Sin 33(3):312–323. https://doi.org/10.1038/aps.2011.186. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077135/pdf/aps2011186a.pdf
Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Jean-Marc G, Chang WC, Pei Y, McCarthy KD, Nissenson RA, Wess J, Bockaert J, Roth BL (2008) Engineering GPCR signaling pathways with RASSLs. Nat Methods 5:673–678. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703467/pdf/nihms-116865.pdf
Dobrzanski G, Kossut M (2017) Application of the DREADD technique in biomedical brain research. Pharmacol Rep 69(2):213–221. https://www.sciencedirect.com/science/article/abs/pii/S1734114016301633?via%3Dihub
Drinovec L, Kubale V, Larsen JN, Vrecl M (2012) Mathematical models for quantitative assessment of bioluminescence resonance energy transfer: application to seven transmembrane receptors oligomerization. Front Endocrinol 104(3):1–10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428587/pdf/fendo-03-00104.pdf
Eldridge MAG, Lerchner W, Saunders RC, Kaneko H, Krausz KW, Gonzalez FJ, Ji B, Higuchi M, Minamimoto T, Richmond BJ (2016) Disruption of relative reward value by reversible disconnection of orbitofrontal and rhinal cortex using DREADDs in rhesus monkeys. Nat Neurosci 19:37–39. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866611/pdf/nihms737321.pdf
Farrell MS (2011) Using DREADDs to isolate internal clocks. Front Integr Neurosci 5:87. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245628/pdf/fnint-05-00087.pdf
Farrell MS, Roth BL (2013) Pharmacosynthetics: reimagining the pharmacogenetic approach. Brain Res 1511:6–20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562395/pdf/nihms-413845.pdf
Ferguson SM, Neumaier JF (2012) Grateful DREADDs: engineered receptors reveal how neural circuits regulate behavior. Neuropsychopharmacology 37(1):296–297. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238068/pdf/npp2011179a.pdf
Ferguson SM, Eskenazi D, Ishikawa M, Wanat MJ, Phillips PE, Dong Y, Neumaier JF (2011) Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci 14:22–24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058296/pdf/nihms245934.pdf
Gomez JL, Bonaventura WL, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A, Michaelides M (2017) Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science 357:503–507. https://www.science.sciencemag.org/content/357/6350/503.full
Grayson DS, Bliss-Moreau E, Machado CJ, Bennett J, Shen K, Grant KA, Fair DA, Amaral DG (2016) The rhesus monkey connectome predicts disrupted functional networks resulting from pharmacogenetic inactivation of the amygdala. Neuron 91:453–466. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233431/pdf/nihms803969.pdf
Guettiera J-M, Gautama D, Scarsellia M, de Azuaa IR, Lia JH, Rosemonda E, Mab X, Gonzalezb FJ, Armbrusterc BN, Lud H, Roth BL, Wessa J (2009) A chemical–genetic approach to study G protein regulation of β cell function in vivo. Proc Natl Acad Sci USA 10:19197–19202. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767362/pdf/zpq19197.pdf
Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC (2014) Insights into the structure of class B GPCRs. Trends Pharmacol Sci 35(1):12–22. https://doi.org/10.1016/j.tips.2013.11.001. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931419/pdf/nihms552172.pdf
Huang CC, Tesmer JJ (2011) Recognition in the face of diversity: interactions of heterotrimeric G proteins and G protein-coupled receptor (GPCR) kinases with activated GPCRs. J Biol Chem 286(10):7715–7721. https://doi.org/10.1074/jbc.R109.051847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048657/pdf/zbc7715.pdf
MacLaren DAA, Browne RW, Shaw JK, Radhakrishnan SK, Khare P, España RA, Clark SD (2016) Clozapine N-oxide administration produces behavioral effects in long–evans rats: implications for designing DREADD experiments. eNeuro 3(5). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089539/pdf/ENEURO.0219-16.2016.pdf
Mahler SV, Vazey EM, Beckley JT, Keistler CR, McGlinchey EM, Kaufling J, Wilson SP, Deisseroth K, Woodward JJ, Aston-Jones G (2014) Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking. Nat Neurosci 17:577–585. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973180/pdf/nihms561759.pdf
Markiceviç M, Fulcher BD, Lewis C, Helmchen F, Rudin M, Zerbi V, Wenderoth N (2020) Cortical excitation: inhibition imbalance causes network-specific functional hypoconnectivity: a DREADD-fMRI study. https://www.biorxiv.org/content/10.1101/492108v1.full.pdf+html
Miller LJ, Dong M, Harikumar KG (2012) Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. Br J Pharmacol 166(1):18–26. https://doi.org/10.1111/j.1476-5381.2011.01463.x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415634/pdf/bph0166-0018.pdf
Nagai Y, Kikuchi E, Lerchner W, Inoue K-i, Ji B, Eldridge MAG, Kaneko H, Kimura Y, Oh-Nishi A, Hori Y, Kato Y, Hirabayashi T, Fujimoto A, Kumata K, Zhang M-R, Aoki I, Suhara T, Higuchi M, Takada M, Richmond BJ, Minamimoto T (2016) PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation. Nat Commun 6:13605. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150653/pdf/ncomms13605.pdf
Nakajima K, Wess J (2012) Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol 82:575–582. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463219/pdf/zmo575.pdf
Oldham WM, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9(1):60–71. https://doi.org/10.1038/nrm2299. https://www.nature.com/articles/nrm2299
Roth BL (2016) DREADDs for neuroscientists. Neuron 89(4):683–694. https://doi.org/10.1016/j.neuron.2016.01.040. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759656/pdf/nihms754820.pdf
Smith KS, Bucci DJ, Luikart BW, Mahler SV (2016) DREADDs: use and application in behavioral neuroscience. Behav Neurosci 130(2):137–155. https://doi.org/10.1037/bne0000135. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792665/
Stachniak TJ, Ghosh A, Sternson SM (2014) Chemogenetic synaptic silencing of neural circuits localizes a hypothalamus: midbrain pathway for feeding behavior. Neuron 82:797–808. https://doi.org/10.1016/j.neuron.2014.04.008
Sternson SM, Roth BL (2014) Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci 37:387–407. https://www.annualreviews.org/doi/10.1146/annurev-neuro-071013-014048
Strader CD, Gaffney T, Sugg EE, Candelore MR, Keyw R, Patchett AA, Dixon RA (1991) Allele-specific activation of genetically engineered receptors. J Biol Chem 266:5–8. https://www.jbc.org/content/266/1/5.full.pdf
Thompson KJ, Khajehali E, Bradley SJ, Navarrete JS, Xi PH, Slocum S, Jin J, Liu J, Xiong Y, Olsen RHJ, Diberto JF, Boyt KM, Pina MM, Pati D, Molloy C, Bundgaard C, Sexton PM, Kash TL, Krashes MJ, Christopoulos A, Roth BL, Tobin AB (2018) DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo. ACS Pharmacol Transl Sci 1:61–72. 8b00012 pmid: 30868140 Roth BL (February 2016). https://www.pubs.acs.org/doi/pdf/10.1021/acsptsci.8b00012
Tse MK, Wong YH (2013) Neuronal functions of activators of G protein signaling. Neurosignals 21(3–4):259–271. https://doi.org/10.1159/000337263. https://www.karger.com/article/pdf/337263
Urban DJ, Roth BL (2015) DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Ann Rev Pharmacol Toxicity 55:399–417. https://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-010814-124803
Vardy E, Elliott Robinson J, Li C, Olsen RHJ, DiBerto JF, Giguere PM, Sassano FM, Huang X-P, Zhu H, Urban DJ, White KL, Rittiner JE, Crowley NA, Pleil KE, Mazzone CM, Mosier PD, Song J, Kash TL, Malanga CJ, Krashes MJ, Roth BL (2015) A new DREADD facilitates the multiplexed chemogenetic interrogation of behavior. Neuron 86:936–946. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441592/pdf/nihms677897.pdf
Whissell PD, Tohyama S, Martin LJ (2016) The use of DREADDs to deconstruct behavior. Front Genet 7:1–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868840/pdf/fgene-07-00070.pdf
Yau JO, Mcnally GP (2015) Pharmacogenetic excitation of dorsomedial prefrontal cortex restores fear prediction error. J Neurosci 35:74–83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605253/pdf/zns74.pdf
Zhu H, Roth BL (2015) DREADD: a chemogenetic GPCR signaling platform. Int J Neuropsychopharmacol 18(1):pyu007. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368861/pdf/pyu007.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Perakis, E. (2021). From G-Protein-Coupled Receptors to Designer Receptors Exclusively Activated by Designer Drugs. In: Vlamos, P., Kotsireas, I.S., Tarnanas, I. (eds) Handbook of Computational Neurodegeneration. Springer, Cham. https://doi.org/10.1007/978-3-319-75479-6_62-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-75479-6_62-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-75479-6
Online ISBN: 978-3-319-75479-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences